Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04209205
Recruitment Status : Recruiting
First Posted : December 24, 2019
Last Update Posted : December 3, 2021
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 18, 2022
Estimated Study Completion Date : May 18, 2022